Xarelto
Bayer/Janssen seek Xa inhibitor antidote
February 6, 2013Research and Development, Sales and Marketing Bayer, Janssen, PRT4445, Xarelto
Bayer HealthCare and Janssen Pharmaceuticals have signed a deal with Portola Pharmaceuticals to evaluate the safety of an investigational antidote …
Bayer cleared of Xarelto ‘breaches’
January 17, 2013Medical Communications, Sales and Marketing Bayer, PMCPA, Xarelto
Bayer has been found not guilty of making multiple breaches of the ABPI Code of Practice following an anonymous complaint …
Further indications for Eliquis
November 22, 2012Sales and Marketing BMS, Eliquis, NVAF, Pfizer, Pradaxa, Xarelto
Bristol-Myers Squibb and Pfizer’s oral blood-thinner Eliquis has been approved in Europe to prevent stroke in patients with nonvalvular atrial …
Xarelto gets new EU approval
November 21, 2012Sales and Marketing AF, Bayer, DVT, Xarelto
Bayer’s oral anticoagulant Xarelto has extended its licence in Europe to treat pulmonary embolism (PE) and prevent recurrent deep vein …
Further US approval for Xarelto
November 5, 2012Sales and Marketing Eliquis, FDA, Pradaxa, Xarelto
US regulators have given the go-ahead to expand the indications for which Janssen Pharmaceuticals and Bayer HealthCare’s oral blood thinner …
Eliquis receives nod in AF
September 24, 2012Sales and Marketing BMS, CHMP, Eliquis, Pfizer, Pradaxa, Xarelto
Bristol-Myers Squibb and Pfizer have received a boost with the CHMP’s recommendation that their co-marketed oral anticoagulant Eliquis should gain …
Bayer raises guidance after strong sales
July 31, 2012Sales and Marketing Bayer, Nexavar, Q2, Xarelto, Yasmin
The Bayer Group has raised its full-year guidance for 2012 following positive results in the second quarter. This is despite …
Bayer guilty of multiple Code breaches
July 30, 2012Medical Communications, Sales and Marketing ABPI Code, Bayer, Xarelto, breach, clause
Bayer Healthcare has admitted to 12 breaches of the ABPI Code after one of its staff developed and distributed drug …
NICE yes for Xarelto to treat blood clots
July 25, 2012Sales and Marketing Bayer, DVT, NHS, NICE, Pradaxa, VTE, Xarelto
NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT). The watchdog said in …
New J&J chief still struggling with scandals
July 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Risperdal, Weldon, Xarelto, Zytiga
Johnson & Johnson has just released its Q2 figures showing sales fell back in the second quarter, a 3.5% growth …
Priority review for Xarelto’s new indications
July 10, 2012Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Boehringer, Eliquis, FDA, Janssen, Pradaxa, Xarelto
Xarelto is to be given a FDA fast-track review for a range of anti-blood clotting uses. Xarelto (rivaroxaban) gained its …
FDA delays Eliquis approval
June 26, 2012Sales and Marketing BMS, Eliquis, FDA, Pfizer, Xarelto
The FDA has asked Pfizer and Bristol-Myers Squibb for more information about its key blood thinner Eliquis. The US regulator …
FDA rejects licence extension for Xarelto
June 26, 2012Sales and Marketing ACS, Bayer, FDA, J&J, JJ, Pradaxa, Xarelto
The FDA has set a Complete Response Letter to Bayer and J&J over its blood thinner Xarelto. The firms, which …
UK Prix Galien shortlist announced
May 30, 2012Business Services, Medical Communications, Research and Development, Sales and Marketing Bayer, Janssen, Xarelto, awards, prix galien
The UK award for the most innovative new drug has been moved a step closer with the release of a …
NICE recommends Xarelto for stroke prevention
May 23, 2012Sales and Marketing Bayer, DVT, NICE, Pradaxa, Xarelto, anticoagulant
NICE is recommending Bayer’s anticoagulant pill Xarelto to help reduce the risk of stroke in certain patients. The watchdog’s final …
Latest content
FibroFind appoints Lee Borthwick as CEO
